**1. Introduction**

Heart failure (HF) is one of the most important causes of morbidity and mortality in developed countries [1]. The improvement in care of cardiac diseases has significantly reduced acute mortality of this condition, in turn, increasing chronic HF prevalence [2]. Hospitalizations for

© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HF are similarly increasing, resulting in very high costs for national health systems [3]. Despite developments in drug therapies and the widespread use of implantable cardiac devices, outcomes remain poor [4]. Several transcatheter implantable devices have recently emerged in an attempt to improve the prognosis and quality of life of such patients. In this chapter, we will review the percutaneous treatment alternatives for mitral and tricuspid regurgitation (TR) associated with advanced HF.
